{"title": "CRB-0401 by China Resources Pharmaceutical Group for Non-Small Cell Lung Cancer: Likelihood of Approval", "author": "Kgi-Admin", "url": "https://www.pharmaceutical-technology.com/uncategorized/crb-0401-china-resources-pharmaceutical-group-non-small-cell-lung-cancer-likelihood-of-approval/", "hostname": "pharmaceutical-technology.com", "description": "CRB-0401 is under clinical development by China Resources Pharmaceutical Group and currently in Phase II for Non-Small Cell Lung Cancer.", "sitename": "Pharmaceutical Technology", "date": "2023-08-28", "cleaned_text": "clinical development by China Resources Pharmaceutical Group and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how CRB-0401's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. [Buy the report here.](https://www.globaldata.com/store/report/crb-0401-in-non-small-cell-lung-cancer-loa-innovation-and-trend-analysis?utm_source=lgp5-loa&utm_medium=24-234707&utm_campaign=thematic-report-hyperlink) GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. CRB-0401 overview CRB-0401 is under development for the treatment of non-small cell lung cancer. China Resources Pharmaceutical Group overview China Resources Pharmaceutical Group (CRPGL) is a pharmaceutical company, which offers a range of nutritional supplements. The company involves in the research and development, manufacture, and also distribution of whole-drug products. Its products comprise chemical medicines, biologics, and health food and traditional Chinese medicine, and nutritional products. CRPGL offers products in the form of oral solid dosage, injections, large infusion bags, oral liquid dosage, powder vials, and topical preparations. The company markets its products through logistics, wholesale, retail, and supply chain services in various provinces across China. It supplies products to pharmaceutical dispensers and manufacturers, including distributors, retail pharmacies, and hospitals. CRPGL is headquartered in Wanchai, Hong Kong. For a complete picture of CRB-0401's drug-specific "}